PALISADE BIO INC (PALI) Stock Price, Quote, News and Overview

Company Profile

Palisade Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Carlsbad, California and currently employs 9 full-time employees. The company went IPO on 2006-12-20. Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. The company is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Company Info

PALISADE BIO INC

7750 El Camino Real, Suite 5200

Carlsbad CALIFORNIA 20876 US

CEO: Kenneth Carter

Employees: 9

Company Website: https://palisadebio.com/

Investor Relations: http://investors.palisadebio.com/financial-information/sec-filings

Phone: 18587044900